FoxO-Mediated Defense against Oxidative Stress in Osteoblasts Is Indispensable for Skeletal Homeostasis in Mice  by Ambrogini, Elena et al.
Cell Metabolism
ArticleFoxO-Mediated Defense against Oxidative Stress
in Osteoblasts Is Indispensable
for Skeletal Homeostasis in Mice
Elena Ambrogini,1,6 Maria Almeida,1,6 Marta Martin-Millan,1 Ji-Hye Paik,2,3,4,5 Ronald A. DePinho,2,3,4,5 Li Han,1
Joseph Goellner,1 Robert S. Weinstein,1 Robert L. Jilka,1 Charles A. O’Brien,1 and Stavros C. Manolagas1,*
1Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical
Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
2Belfer Institute for Applied Cancer Science, Harvard Medical School, Boston, MA 02115, USA
3Department of Medical Oncology
4Department of Medicine
5Department of Genetics
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
6These authors contributed equally to this work
*Correspondence: manolagasstavros@uams.edu
DOI 10.1016/j.cmet.2009.12.009SUMMARY
Aging increases oxidative stress and osteoblast
apoptosis and decreases bone mass, whereas fork-
head box O (FoxO) transcription factors defend
against oxidative stress by activating genes involved
in free radical scavenging and apoptosis. Conditional
deletion of FoxO1, FoxO3, and FoxO4 in 3-month-old
mice resulted in an increase in oxidative stress in
bone and osteoblast apoptosis and a decrease in
the number of osteoblasts, the rate of bone forma-
tion, and bone mass at cancellous and cortical sites.
The effect of the deletion on osteoblast apoptosis
was cell autonomous and resulted from oxidative
stress. Conversely, overexpression of a FoxO3 trans-
gene in mature osteoblasts decreased oxidative
stress and osteoblast apoptosis and increased oste-
oblast number, bone formation rate, and vertebral
bone mass. We conclude that FoxO-dependent
oxidative defense provides a mechanism to handle
the oxygen free radicals constantly generated by
the aerobicmetabolism of osteoblasts and is thereby
indispensable for bone mass homeostasis.
INTRODUCTION
Reactive oxygen species (ROS) are continuously generated as
normal by-products of aerobic metabolism and can cause lipid
peroxidation, protein damage, and DNA lesions leading to cell
death, but also serve as signaling molecules at lower concentra-
tions to control cell proliferation and differentiation (Balaban
et al., 2005; Giorgio et al., 2007). Age- or gonadectomy-related
bone loss in mice is associated with increased oxidative stress
(OS) (Lean et al., 2003; Almeida et al., 2007b, 2009a, 2009b;
Manolagas, 2010). Likewise, murine models of premature aging136 Cell Metabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inand signs of oxidative damage exhibit osteoporotic features
(Tyner et al., 2002; De Boer et al., 2002). Moreover, antioxidants
prevent the increased osteoclastogenesis and increased osteo-
blast and osteocyte apoptosis as well as the loss of bone caused
by gonadectomy, supporting the view that OS plays an impor-
tant role in skeletal homeostasis (Lean et al., 2003; Almeida
et al., 2007b).
To counteract the adverse consequences of OS, cells possess
several oxidative defensemechanisms including those governed
by the FoxO family of transcription factors. In mammals, this
family comprises four members: FoxO1/FKHR, FoxO3/FKHRL1,
FoxO4/AFX, and FoxO6 (Greer and Brunet, 2005). FoxO1,
FoxO3, and FoxO4 show broad, overlapping patterns of expres-
sion in developing and adult tissues, whereas FoxO6 is restricted
to specific structures of the developing brain. In the setting of
growth factor stimulation, FoxO1, FoxO3, and FoxO4 are subject
to Akt-mediated phosphorylation, which results in their nuclear
export and inhibition of FoxO-mediated transcription (Brunet
et al., 1999; Kops et al., 1999; Biggs et al., 1999; Tang et al.,
1999; Takaishi et al., 1999). OS, on the other hand, causes the
retention of FoxOs in the nucleus and activation of transcription
by promoting FoxO posttranslational modifications, including
phosphorylation (on amino acid residues distinct from those
phosphorylated by Akt), ubiquitylation, and acetylation (Calnan
and Brunet, 2008; van der Horst and Burgering, 2007). Stress
stimuli override the sequestration of FoxOs in the cytoplasm by
growth factors, both in mammalian cells and in Drosophila
(Brunet et al., 2004; Wang et al., 2005), suggesting that protec-
tion of cells from stress is one of the crucial roles of these evolu-
tionarily conserved proteins. FoxOs mediate OS responses by
regulating the transcription of antioxidant enzymes such as
MnSOD and catalase as well as genes involved in cell cycle,
DNA repair, and life span (Salih and Brunet, 2008; van der Horst
and Burgering, 2007). The importance of the antioxidant proper-
ties of FoxOs in mammalian biology has been recently high-
lighted by the profound effects of the deletion of FoxO3 alone
or the combined deletion of FoxO1, FoxO3, and, FoxO4 in
mice. Indeed, these studies have revealed that FoxOs arec.
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Figure 1. Bone Mass Is Decreased
Following FoxO Deletion
(A–D) Twelve-week-old female and male mice
were injected with pI-pC and sacrificed 5 weeks
later.
(A) mRNA levels of FoxOs in calvaria (calv),
vertebra (vert), liver, or spleen from male mice
were determined by qRT-PCR (n = 8 mice/group).
(B) BMDs determined by DEXA 1 day before and
5 weeks following pI-pC injections (n = 10–17
mice/group). *p < 0.05 versus respective Mx-Cre
by Student’s t test.
(C) Cortical widthmeasured bymicro-CT in femurs
(n = 10–17 mice/group). *p < 0.05 versus respec-
tive Mx-Cre by Student’s t test.
(D) Histomorphometric analysis of longitudinal
undecalcified sections of L1-L3 vertebrae of male
mice (n = 6–7 mice/group). BA/TA, bone area per
tissue area; Tb, trabecular.
*p < 0.05 by Student’s t test. Bars represent
mean ± SD.
Cell Metabolism
FoxOs and Skeletal Homeostasisindispensable for normal erythropoiesis and hematopoietic stem
cell quiescence and survival because of their ability to prevent
excessive levels of ROS (Marinkovic et al., 2007; Tothova
et al., 2007).
b-catenin—a factor required for osteoblast differentiation
(Glass et al., 2005)—is essential for ROS-induced FoxO activa-
tion (Essers et al., 2005). In osteoblastic cell models, OS induces
the association of FoxOs with b-catenin and promotes FoxO-
mediated transcription at the expense of b-catenin/T cell-
specific transcription factor (TCF)-mediated transcription and
osteoblast differentiation (Almeida et al., 2007a, 2009a). The
negative effect of ROS on TCF transcription is abrogated by
raising the level of b-catenin, suggesting that a limited pool of
active b-catenin is diverted from TCF to FoxO transcription under
stress conditions (Manolagas and Almeida, 2007; Hoogeboom
and Burgering, 2009). FoxOs are also known to suppress the
expression and transcriptional activity of PPARg, which is
a potent repressor of osteoblastogenesis (Dowell et al., 2003;
Armoni et al., 2006; Akune et al., 2004). Together, these observa-
tions prompt speculation that FoxOs play an important role in
bone biology by enabling the maintenance of a physiologically
appropriate life span of mature osteoblasts through their oxida-
tive defense activities. In addition, FoxOs may control the gener-
ation of new osteoblasts from their mesenchymal stem cell
progenitors by modulating their proliferation and/or differentia-
tion through their antioxidant properties or via modulating the
activity of other transcription factors such as b-catenin or
PPARg.Cell Metabolism 11, 136–146RESULTS
FoxO3 Is the Predominant FoxO
in Bone and Bone Cells
Quantitative (q)RT-PCR analysis of
whole-tissue RNA revealed that all three
FoxO genes were expressed in calvariae
and vertebrae, with FoxO3 showing the
most abundant expression (2- to 3-fold
higher than FoxO1 and FoxO4) (seeFigure S1A available online). FoxO1, FoxO3, and FoxO4 expres-
sion remained constant between 4 and 26 months of age, as
determined in two independent experiments (Figure S1B).
Consistent with the whole-bone findings, FoxO3 expression
was 2-fold higher than FoxO1 and FoxO4 in bone marrow-
derived osteoclasts (Figure S1C) or in calvaria- or bone
marrow-derived osteoblastic cells (Figure S1D). Thus, all three
FoxOs are expressed in bone cells, and FoxO3 is the predomi-
nant FoxO family member.
Loss of FoxO Signaling Causes Loss of Bone Mass
To elucidate the role of FoxOs in bone, we characterized the
skeletal phenotype of mice in which the three main FoxO genes
FoxO1, FoxO3, and FoxO4 were conditionally deleted. For this
purpose, we used 12-week-old Mx-Cre+;FoxO1,3,4L/L mice
harboring the interferon-inducible transgene Mx1-Cre and
conditional alleles for each of the FoxO genes and Mx-Cre-;
FoxO1,3,4L/L littermate controls, hereafter designated Mx-Cre+
and Mx-Cre, respectively (Paik et al., 2007). Five weeks after
injection of polyinosine-polycytidylic acid (pI-pC), used to acti-
vate the transgene and consequently the deletion of the three
FoxO genes, the levels of expression of FoxO1, FoxO3, and
FoxO4 were decreased by 60%–75% in calvaria and vertebrae
ofMx-Cre+ mice (Figure 1A). The efficiency of deletion of FoxOs
in bone was comparable to that of spleen but less than in liver
(Figure 1A). Body weight was not affected by FoxO deletion in
Mx-Cre+ females or males (Figure S2A). Five weeks after FoxO
deletion, however, male and female Mx-Cre+ mice exhibited, February 3, 2010 ª2010 Elsevier Inc. 137
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Figure 2. Deletion of FoxOs Increases
Oxidative Stress and Decreases Bone
Formation
(A–C) Measurements were made using bone from
the animals described in Figure 1.
(A) Histomorphometric analysis of longitudinal
undecalcified sections of L1-L3 vertebrae of
male mice (n = 6–7 mice/group). Ob = osteoblast;
Oc = osteoclast.
(B) p66shc phosphorylation determined by western
blot in vertebral lysates; each lane represents one
animal. The mean ratio ± SD of phosphorylated
p66shc to b-actin is depicted numerically at the
bottom of the corresponding blots.
(C) Osteoblasts and osteocyte apoptosis in
sections of the samemice as in (A). In the photomi-
crographs apoptotic osteocytes and osteoblasts
(stained brown by ISEL, original magnification
3630) are indicated by the arrows (n = 7–8 mice/
group).
*p < 0.05 by Student’s t test. Bars represent
mean ± SD.
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FoxOs and Skeletal Homeostasisa significantly lower bonemass, as documented by a decrease in
total and femoral bone mineral density (BMD) by dual energy
X-ray absorptiometry (DEXA) (Figure 1B and Table S1). Spinal
BMD also decreased in male animals. Deletion of FoxOs led to
a decrease in femoral cortical width in female and maleMx-Cre+
mice as determined by compartment-specific analysis by micro-
CT (Figure 1C). Femoral cancellous bone volume was also
decreased but to a lesser extent, and consistent with this,
Mx-Cre+ mice exhibited decreased trabecular number and
increased trabecular separation (Figure S2B). Histomorphomet-
ric analysis of the vertebrae of male mice confirmed the effect of
the deletion on bone mass by revealing a significant reduction in
cancellous bone area as well as a decrease in trabecular width
and number and increased trabecular separation (Figure 1D).
In agreement with the decreased cancellous bone mass, osteo-
blast number, osteoid perimeter, and bone formation rate (BFR)
were also reduced (Figure 2A). In contrast, the number of osteo-
clasts in cancellous bone was not affected by deletion of FoxOs
(Figure 2A).
OS and Osteoblast Apoptosis Are Increased
in FoxO-Deficient Mice
Because of the well-known antioxidant role of FoxOs in other
tissues (Marinkovic et al., 2007; Tothova et al., 2007), we exam-
ined the levels of OS in the bone of the FoxO-deletedmice. FoxO
deletion resulted in increased phosphorylation of p66shc—
a robust marker of OS (Migliaccio et al., 1999; Giorgio et al.,
2005)—in vertebral lysates from male and female Mx-Cre+
mice (Figure 2B). In agreement with our earlier findings that
increased OS in bone promotes osteoblast and osteocyte138 Cell Metabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inc.apoptosis (Almeida et al., 2007b), the
prevalence of apoptosis of both these
cell types was increased in vertebral
cancellous bone from Mx-Cre+ mice as
a consequence of the loss of FoxO func-
tion (Figure 2C). This result suggests that
decreased osteoblast survival is respon-
sible, at least in part, for the decreased osteoblast number,
bone formation, and bone mass.
To investigate whether the protective actions of FoxOs
against OS and osteoblast apoptosis in bone were cell autono-
mous,weculturedcalvaria- or bonemarrow-derivedosteoblastic
cells fromMx-Cre+ orMx-Cremice. The efficiency of deletion of
FoxOs in calvaria- or bone marrow-derived cells from Mx-Cre+
mice was about 50% and 80%, respectively, as measured by
qRT-PCR. The decrease of the three FoxOs was confirmed by
western blotting (Figure 3A and Figure S3A). Similar to the
in vivo data, apoptosis of either calvaria- or bonemarrow-derived
osteoblastic cells from Mx-Cre+ mice was increased as
compared to cells from control mice (Figure 3B and Fig-
ure S3B). The higher prevalence of apoptosis of FoxO-deleted
cells was due to increased OS, as the antioxidant N-acetyl-
cysteine (NAC) abrogated the proapoptotic effect of FoxO dele-
tion in calvaria-derived cells (Figure 3B). In agreement with this
finding, OS was increased in calvaria-derived osteoblasts from
Mx-Cre+mice, asevidencedbya2-foldhigher basalp66shcphos-
phorylation (Figure 3C). As with apoptosis, addition of NAC abro-
gated the increased p66shc phosphorylation, a finding consistent
with the view that FoxOs attenuate osteoblastic cell apoptosis
through a cell-autonomousmechanism thatminimizes OS. There
was no difference between theMx-Cre+ andMx-Cremice in the
rate of the proliferation of cells in these cultures (data not shown).
The number of osteoblasts present in bone is determined by
their rate of generation and their life span. To examine whether
the lower osteoblast number in Mx-Cre+ mice could result in
part from a decrease in osteoblastogenesis, we examined the
expression of Runx2 and Osterix—two transcription factors
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Figure 3. ROS-Induced Apoptosis Is
Increased in Osteoblastic Cells from FoxO-
Deleted Mice
(A–D) Cells were obtained from themice described
in Figure 2.
(A) mRNA levels of FoxOs by qRT-PCR and protein
levels of FoxOs by western blot in calvaria-derived
osteoblastic cells cultured for 8 days. *p < 0.05 by
Student’s t test.
(B) Caspase-3 activity in cells described in (A),
cultured in the presence of vehicle or NAC
(1 mM) for 24 hr. *p < 0.05 versus veh inMx-Cre,
#p < 0.05 versus veh in Mx-Cre+ by ANOVA.
(C) p66shc phosphorylation determined by western
blot in lysates from calvaria cells described in (B).
The ratio of phosphorylated p66shc to b-actin is
depicted numerically at the bottom of the corre-
sponding blots.
(D) mRNA levels of the indicated genes in bone
marrow-derived stromal cells cultured for 8 days.
*p < 0.05 by Student’s t test.
(E) Bone marrow-derived stromal cells were
treated with vehicle or RGL (5 nM/ml) for
11 days. Lipid was visualized with oil red O and
quantified as described in the Experimental Proce-
dures. *p < 0.05 versus RGL inMx-Cre, yp < 0.05
versus vehicle in Mx-Cre by ANOVA.
Bars represent mean ± SD.
Cell Metabolism
FoxOs and Skeletal Homeostasisrequired for the commitment and differentiation of mesenchymal
progenitors to cells of the osteoblastic lineage (Karsenty, 2008).
Runx2 and Osterix mRNA levels were decreased as a result of
FoxO deletion in bone marrow-derived stromal cells, as well as
the levels of the osteoblast marker alkaline phosphatase (Fig-
ure 3D). In addition, the same cells displayed increased expres-
sion of PPARg2, a nuclear receptor that downregulates osteo-
blastogenesis (Akune et al., 2004) (Figure 3D). Consistent with
the increased PPARg2 expression in the Mx-Cre+ mice, the
proadipogenic ligand rosiglitazone (RGL) caused a greater
increased in the number of adipocytes in bone marrow-derived
stromal cell cultures from these mice as compared to the
controls (Figure 3E).
Deletion of FoxOs alters the number of hematopoietic lineage
cells (Tothova et al., 2007). Prompted by this evidence, we
quantified the number of osteoclast progenitors present in the
bone marrow of Mx-Cre+ mice. As shown in Figure 4A, the
mRNA and protein levels of the three FoxOs were dramatically
diminished in cultured osteoclasts from Mx-Cre+ mice, similar
to the case of hematopoietic stem cells (Tothova et al., 2007).
Osteoclasts from Mx-Cre+ mice exhibited an increase in the
rate of apoptosis (Figure 4B). This was confirmed by the lower
expression of the osteoclast-specific markers like the calcitonin
receptor, tartrate-resistant acid phosphatase (TRAP), and
cathepsin K in parallel cultures (Figure 4C). In line with evidence
that FoxO3 binds to and suppresses the FasL promoter (Jonsson
et al., 2005), the increased osteoclast apoptosis was associated
with a 4-fold increase in FasL mRNA. Osteoclast progenitor
number was increased as a result of FoxO deletion (Figure 4D).
Gain of FoxO3 Function in Osteoblasts Causes
an Increase in Bone Mass
To seek independent confirmation of the role of FoxOs in bone
formation and homeostasis, we generated mice that condition-Cell Mally overexpress FoxO3 in cells of the osteoblast lineage
(Figure 5A). This was accomplished by crossing mice with
a conditionally activated wild-type FoxO3 transgene (FoxO3C)
with mice expressing Cre recombinase under the control of the
osteocalcin (OCN) promoter. This promoter targets the expres-
sion of Cre to osteoblast-lineage cells at later stages of differen-
tiation. Consistent with this, the FoxO3 transgene was highly
expressed in calvariae or vertebrae from 1-month-old OCN-Cre;
FoxO3C mice but was undetectable in liver or spleen. As
expected, the transgene was also undetectable in all tissues
from littermate controls harboring only the OCN-Cre transgene
(Figure 5B). The expression of FoxO target genes, like Gadd45
and catalase, was increased in calvariae of OCN-Cre;FoxO3C
mice, confirming the functionality of the transgene (Figure 5C).
To further examine the functionality of the transgene, we used
adenovirus (Ad)-Cre infection to activate it in calvaria cells from
FoxO3C mice. Transfection of Ad-Cre-infected cells with a
FoxO-responsive luciferase (luc) reporter construct led to a 2-
fold enhancement of FoxO-directed transcriptional activity
(Figure 5D).
Overexpression of FoxO3 in osteoblasts led to a significant
increase in bone mass in the vertebrae, as determined by BMD
at 16 weeks of age in the female, but not in the male, mice
(Figure 6A). Nonetheless, an increase in cancellous bone mass
(as determined by the measurement of bone volume over total
volume) could be detected by micro-CT in both sexes, most
likely reflecting the three-dimensional advantage of the micro-
CT measurement (Figure 6B). Female or male OCN-Cre;FoxO3C
mice also exhibited increased trabecular number, as com-
pared to littermate controls, while trabecular separation was
decreased, but this latter change was significant only in the
male (Figure 6C). Vertebral BMD in female mice harboring the
FoxO3C transgene without Cre activation was similar to wild-
type littermates, demonstrating that the insertion site of theetabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inc. 139
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Figure 4. Osteoclast Progenitor Number
and Mature Osteoclast Apoptosis Are
Increased Following FoxO Deletion
(A–D) Cells were obtained from the mice described
in Figure 2.
(A) mRNA levels of FoxOs by qRT-PCR and protein
levels of FoxOs by western blot in mature osteo-
clasts generated from nonadherent bone marrow
cells cultured with M-CSF and RANKL for 5 days;
ND, not detected.
(B and C) (B) Caspase-3 activity and (C) mRNA
levels of the indicated genes in cells described in
(A). CtR, calcitonin receptor; CtsK, cathepsin K.
(D) Number of TRAP-positive cells generated from
bone marrow cells cultured with M-CSF and
RANKL for 6 days. TRAP, tartrate-resistant acid
phosphatase.
*p < 0.05 by Student’s t test. Bars represent
mean ± SD.
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FoxOs and Skeletal HomeostasisFoxO3C transgene has no effect on bone mass (Figure S4A).
In contrast to the lumbar spine BMD, there was no difference
in femoral bone mass between the experimental and the control
mice by BMD (data not shown) or micro-CT (Figure S4B). Histo-
morphometric analysis of vertebral bone independently con-
firmed that FoxO3 gain of function in osteoblasts led to an
increase in bone mass as demonstrated by an increase in
cancellous bone area (BA/TA) and trabecular number, as well
as a decrease in trabecular separation (Figure 6D).
Consistent with the gain in bone mass, the transgenic mice
exhibited higher numbers of osteoblasts and BFR in cancellous
bone (Figure 7A). Moreover, in a diametrically opposite manner
to the deletion model, FoxO3 overexpression in mature osteo-
blasts resulted in decreased phosphorylation of p66shc in verte-
bral lysates from the OCN-Cre;FoxO3C mice (Figure 7B). In line
with the evidence for the decrease in OS in the bones of the
OCN-Cre;FoxO3C mice, the prevalence of osteoblast apoptosis
was diminished, whereas osteocyte apoptosis was not affected
(Figure 7C).
To demonstrate that the overexpression of FoxO3 in osteo-
blasts did actually enhance defense against OS and thereby pro-
tected osteoblasts from OS-induced apoptosis, we cultured
bone marrow-derived osteoblastic cells from the control and
the OCN-Cre;FoxO3C mice for 18 days in ascorbic acid (Figures
7D and 7E). As expected, progression of osteoblast differentia-
tion under these culture conditions (and thereby an increase in
the number of osteocalcin expressing cells) led to the expression
of the FoxO3 transgene in cells from the OCN-Cre;FoxO3C, but
not in cells from control mice as shown in Figure 7D by qRT-
PCR and western blot for HA and FoxO3. For the western blot
of Figure 7D, we have utilized an anti-FoxO3 antibody that recog-140 Cell Metabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inc.nizes both the human protein produced
by the transgene as well as the endoge-
nous mouse protein. Thus, the increased
signal intensity observed in the transgene
lane reflects the sum of both proteins and
thereby an increase in overall FoxO3
expression in the cells from the transgenic
mice. As shown in Figure 7E, osteoblastsfrom the OCN-Cre;FoxO3C mice exhibited resistance to
apoptosis induced by a range of H2O2 concentrations.
Finally, based on our previous observations that FoxOs can
divert b-catenin from TCF- to FoxO-mediated transcription and
by this mechanism decrease the expression of the antiosteo-
clastogenic factor osteoprotegerin (OPG) and consequently
increase osteoclast numbers (Glass et al., 2005), we examined
the number of osteoclast progenitors in the bone marrow and
mature osteoclasts in vertebral bone sections of the FoxO3 over-
expressing mice. Unexpectedly, these mice displayed lower
progenitors and lower osteoclast numbers (Figure 7F). This
decrease could not be explained by changes in the production
of osteoclastogenic cytokines by osteoblastic cells, because
we observed no changes in the mRNA levels of RANKL, OPG,
or M-CSF in vertebral bone from OCN-Cre;FoxO3C mice (data
not shown).
DISCUSSION
FoxOs translate environmental stimuli, such asOS and hormonal
changes, into dynamic gene expression programs involved in
many physiological as well as pathological processes (Salih
and Brunet, 2008; Dansen and Burgering, 2008; van der Horst
and Burgering, 2007). Based on this and evidence that
decreased defense against OS is responsible, at least in part,
for the adverse effects of aging and sex steroid deficiency on
the murine skeleton, we have genetically manipulated FoxOs in
mice and investigated the impact of such manipulation on skel-
etal homeostasis. Specifically, we hypothesized that if one were
to remove an important defense mechanism against OS from
bone cells, one may recapitulate at least some of the adverse
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Figure 5. Generation of FoxO3C Transgenic
Mice
(A) Mice harboring a transgene consisting of a
transcriptional/translational stop cassette, flanked
by loxP sites, inserted between the broadly
expressed hybrid CMV-chicken b-actin promoter
and a cDNA encoding an HA-tagged human
FoxO3 wild-type, designated FoxO3C mice, were
crossed with mice expressing the Cre recombi-
nase under the control of the OCN promoter. The
loxP-flanked stop cassette is removed only in cells
expressing Cre resulting in FoxO3 expression in
that cell type. PA, polyadenilation site.
(B) mRNA levels of the FoxO3 transgene in
calvaria, vertebra (L5), liver and spleen of
4-week-old mice determined by qRT-PCR
(n = 3 mice/group); ND, not detected.
(C) mRNA levels of the indicated FoxO target
genes in calvaria from 4-week-old mice
(n = 3 mice/group).
(D) Calvaria-derived osteoblastic cells isolated
from newborn FoxO3C and wild-type littermates
infected with Ad-Cre for FoxO3 overexpression
and transfected with a FoxO-luc reporter
construct. Luc activity was measured 24 hr later.
*p < 0.05 by Student’s t test. Bars represent
mean ± SD.
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FoxOs and Skeletal Homeostasiseffects of aging on bone in young mice. Our results demonstrate
that conditional deletion of the three broadly expressed genes,
FoxO1, FoxO3, and FoxO4, in young adult mice or targeted over-
expression of FoxO3 in osteoblasts leads to significant changes
in bone mass. Specifically, loss of FoxO function in 3-month-old
mice for a period of 5 weeks results in increased OS in bone as
well as increased osteoblast and osteocyte apoptosis and an
osteoporotic phenotype characterized by decreased bone
mass at both cancellous and cortical sites. We also show that
the increased osteoblast apoptosis following the triple FoxO
deletion is cell autonomous and the result of increased OS, asA B
OCN-Cre OCN-Cre;FoxO3
C
BMD
65 
BV/TV
55
OCN
Micro-CT
OCN-Cre
m
g
/
c
m
2
45
50
55
60
%
25
35
45 
malefemale malefemale

Tb separation Tb number 
Micro-CT D
AT/AB Tb num
20 5 5
C Vertebral bon
/
m
m
4
5
6 
μ
m
160
200
240

%
/
m
m

12
14
16
18
3.5
4.5
.
malefemale malefemale
10
Cell Mthe rate of osteoblast apoptosis of the FoxO-deficient osteo-
blasts in ex vivo cultures can be reverted to normal by the addi-
tion of the antioxidant NAC.
In sharp contrast to the increased OS and osteoblast
apoptosis, decreased osteoblast number and bone formation,
and the loss of bone mass following the loss of FoxO function,
overexpression of FoxO3 in mature osteoblasts led to opposite
effects: decreased OS and osteoblast apoptosis, increased
osteoblast number and bone formation, and increased bone
mass. Albeit increased bone mass was detectable in the verte-
brae but not in the femur, perhaps because of the high variability-Cre;FoxO3
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Osteoblasts Protects against Oxidative
Stress-Induced Apoptosis
(A–C) Measurements weremade using bones from
the animals described in Figure 6.
(A) Histomorphometric analysis of longitudinal
undecalcified sections of L1-L3 vertebrae of male
mice (n = 7 mice/group). Ob, osteoblasts; BFR,
bone formation rate.
(B) p66shc phosphorylation determined by western
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animal. The mean ratio ± SD of phosphorylated
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bottom of the corresponding blots.
(C) Osteoblasts and osteocyte apoptosis in
sections of the same mice were as in (A).
(D) mRNA levels of FoxO3 transgene by qRT-PCR
and protein levels of HA-FoxO3 and Foxo3 by
western blot in bone marrow-derived osteoblastic
cells cultured for 18 days with ascorbic acid.
(E) Caspase-3 activity in cells described in (D),
cultured in the presence of vehicle or H2O2 at the
indicated concentrations for 16 hr. *p < 0.05 versus
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(F) (Left panel) Number of TRAP-positive cells
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M-CSF and RANKL for 6 days. (Right panel) Oste-
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sections as in (A). TRAP, tartrate-resistant acid
phosphatase; Oc, osteoclast.
*p < 0.05 by Student’s t test. Bars represent
mean ± SD.
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FoxOs and Skeletal Homeostasisof the measurement at the latter site during growth. An alterna-
tive explanation for the manifestation of the gain of FoxO3 func-
tion only in vertebrae may be the dramatically higher rate of turn-
over and the basal rate of osteoblast apoptosis in cancellous
versus the periosteal compartment (Jilka et al., 2009) and the
fact that cancellous bone makes a larger contribution to BMD
in the vertebrae than in the femur.
Collectively, the findings of this paper suggest that FoxOs are
constantly defending against increased OS in osteoblasts,
thereby assuring a normal healthy life span. In support of this
conclusion, earlier work from our group and others over the years
has established that apoptosis is the fate of the majority (60%–
80%) of mature osteoblasts (Jilka et al., 2007) and that this
process is regulated by all major factors that influence skeletal
homeostasis, including systemic hormones; glucocorticoid
administration; locally produced factors like IL-6 type cytokines,
IGF-I, Wnts, and their antagonists; parathyroid related peptide;
mechanical forces; and OS (Jilka et al., 2008). Consistent with
the contention that loss of FoxOs increases OS and thereby
decreases the life span of osteoblasts, the number of mature
osteoblasts in bone sections from the FoxO-deficient mice was
decreased, and as a consequence their work output (i.e., the142 Cell Metabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inc.synthesis and mineralization of the bone
matrix) was compromised.
Similar to our findings with osteoblasts,
FoxOs promote mammalian cell survival
by attenuating OS in other cell types(Tothova and Gilliland, 2007). Nonetheless, this effect is highly
dependent on the cell type and even the tissue in which a partic-
ular cell type resides. For example, loss of FoxO function
promotes murine hematopoietic stem cell apoptosis but
decreases the apoptosis of thymocytes in the same animals
(Paik et al., 2007; Tothova et al., 2007). More strikingly, loss of
FoxOs decreases the apoptosis of endothelial cells from the liver
but has no effect on endothelial cells residing in the lungs (Paik
et al., 2007).
Osteoblast generation (determined by the expression of
several lineage specific markers) in ex vivo cultures of osteo-
blastic progenitors derived from the bone marrow of FoxO-defi-
cient mice was attenuated as compared to the control mice.
Specifically, Runx2 and Osterix expression as well as alkaline
phosphatase, markers of osteoblast differentiation, were
decreased. This could result from either an increase in the
apoptosis of these progenitors or attenuation of their differentia-
tion. In support of the latter explanation, deletion of FoxOs
caused an increase of PPARg—a nuclear receptor that stimu-
lates adipogenesis (Tontonoz and Spiegelman, 2008) while it
represses osteoblastogenesis (Akune et al., 2004) and is toni-
cally suppressed by FoxOs (Dowell et al., 2003; Armoni et al.,
Cell Metabolism
FoxOs and Skeletal Homeostasis2006). Moreover, cells from the FoxO-deficient mice exhibited
increased adipogenic potential in response to the PPARg ligand
RGL. Hence, increased adipocyte differentiation at the expense
of osteoblast differentiation from their common mesenchymal
progenitors may have contributed to the decreased osteoblast
number and bone formation in these mice.
We and others have demonstrated that both old age and acute
loss of sex steroids in mice lead to increased OS and an increase
in the prevalence of osteoblast and osteocyte apoptosis, and
that antioxidants prevent the increased osteoblast and osteo-
cyte apoptosis as well as the loss of bone caused by gonadec-
tomy (Almeida et al., 2007b; Lean et al., 2003). In addition,
FoxO transcriptional activity, as measured by the expression of
the Gadd45 gene expression, was increased in the aged mice
of our earlier studies (Almeida et al., 2007a). The most likely
explanation for the inability of FoxOs to prevent osteoblast
apoptosis in old age is that the defense provided by these factors
is overwhelmed by the high level of OS, or that OS activates other
pathways that interfere with the activity of FoxOs, or both. Exten-
sive evidence indicates that ROS-induced p66shc activation
leads to FoxO inactivation via Akt-mediated FoxO phosphoryla-
tion (Nemoto and Finkel, 2002; Smith et al., 2005). Moreover,
ROS-induced stimulation of NF-kB may lead to IKK-mediated
phosphorylation and inhibition of Foxo3 activity, at least in part
by targeting it to ubiquitin-dependent degradation (Hu et al.,
2004). Increased phosphorylation of p66shc and increased
activity of NF-kB are common features of old age and sex steroid
deficiency (Almeida et al., 2007b; Biswas et al., 2005; Adler et al.,
2007; De Bosscher et al., 2006). Hence, several counteracting
mechanisms can account for the overwhelming of FoxOs’ ability
to thwart osteoblast apoptosis in old age.
Deletion of FoxOs also caused an increase in mature osteo-
clast apoptosis, perhaps secondary to the observed increase
in FasL production. This latter finding is in agreement with the
observation that FoxO3 can bind and suppress the FasL
promoter in neutrophils, whereas deletion of FoxO3 results in
elevated expression of FasL and increased neutrophil apoptosis
(Jonsson et al., 2005). In support of this contention, FasL is an
important proapoptotic signal for osteoclasts, and mice lacking
Fas have increased osteoclast numbers and decreased bone
mass (Wu et al., 2003). Moreover, modulation of FasL signaling
by estrogens may represent an important mechanism of the
proapoptotic effect of these hormones on osteoclasts (Manola-
gas, 2000; Nakamura et al., 2007). The stimulatory effect of the
FoxO deletion on osteoclast apoptosis was accompanied by
an increase in osteoclast progenitors, most likely due to the
expansion of myeloid progenitors, described earlier by Tothova
et al. (Tothova et al., 2007). In spite of these changes, the number
of osteoclasts in cancellous bone of theMx-Cre+mice was unal-
tered, suggesting that the two changesmay have cancelled each
other. Genetic manipulation of FoxOs exclusively in cells of the
osteoclast lineage in future work should help to explain these
phenomena and their biologic relevance.
Lastly, overexpression of FoxO3 in osteoblasts led to a
decrease in osteoclast numbers, which was unexpected, con-
sidering the inhibitory effect of FoxOs on canonical Wnt signaling
and evidence that b-catenin reduces the levels of OPG (a direct
target of b-catenin/TCF transcriptional activity) and increases
RANKL and consequently osteoclast numbers in bone (GlassCell Met al., 2005; Holmen et al., 2005). YetOPG or RANKL expression
was not altered in the bone of our OCN-Cre;FoxO3C mice. This
latter finding suggests that increased FoxO3 transcriptional
activity in mature osteoblasts controls osteoclastogenesis inde-
pendently of the canonical Wnt signaling. Instead, FoxO3 over-
expression may decrease osteoclast number by decreasing
ROS in the bone microenviroment. This suggestion is supported
by mounting evidence that mitochondria biogenesis and ROS
are indeed required for osteoclast generation (Garrett et al.,
1990; Levasseur et al., 2003; Bai et al., 2005; Lean et al., 2005;
Lee et al., 2005).
In conclusion, the results reported in this paper strongly
support the working hypothesis that ROS are seminal signals
for the fate of osteoblasts and that inappropriate increase of
ROS adversely affects bone formation. The FoxO family of tran-
scription factors defends against such an increase by constantly
upregulating free radical scavenging and DNA-repair enzymes,
thereby representing an indispensable homeostatic mechanism
for skeletal health.EXPERIMENTAL PROCEDURES
Generation of FoxO3 Transgenic Mice
We generated mice harboring a transgene consisting of a transcriptional/
translational stop cassette, flanked by loxP sites, inserted between the broadly
expressed hybrid CMV-chicken b-actin promoter (Matsuda and Cepko, 2007)
and a cDNA encoding an HA-tagged wild-type human FoxO3 (Figure 5A),
designated FoxO3C mice. HA-FoxO3 (Brunet et al., 1999) was provided by
M. Greenberg, Harvard Medical School (Addgene plasmid 1787). When
crossed with mice expressing the Cre recombinase in a specific cell type,
the loxP-flanked stop cassette is removed only in the cells expressing Cre,
resulting in FoxO3 expression in that cell type (Figure 5A). We generated ten
independent FoxO3C lines using this construct in a C57BL/6 background
and tested the ability of the transgene to be activated in a cell-type-specific
manner by crossing each line with transgenic mice expressing Cre under the
control of the human osteocalcin promoter (OCN-Cre) (Zhang et al., 2002).
A single FoxO3C line demonstrating bone-specific expression (Figure 5A)
was utilized for all the studies described herein. Experimental mice were
generated by crossing homozygous OCN-Cre mice, which are in a FVB/N
background, with hemizygous FoxO3C mice to generate offspring that were
all hemizygous for the OCN-Cre transgene, and 50% of these were also hemi-
zygous for the FoxO3C transgene. Thus all experimental mice were littermates
in an F1 C57BL/6-FVB/N genetic background. Transgenic offspring were iden-
tified by PCR using the following primer sequences: forward (101 bp)
50-GAGTCGCTCGGTACGATTTA-30 reverse (101 bp) 50-CGGGAGGCTAGCA
TAATCAG-30.
Animal Experimentation
Twelve-week-old Mx-Cre+;FoxO1,3,4L/L and Mx-Cre;FoxO1,3,4L/L littermate
control mice, generated as previously described (Paik et al., 2007), received
a total of three intraperitoneal injections of 300 mg of pI-pC (Sigma) adminis-
tered every other day to induce Cre activation. Five weeks later, the animals
were sacrificed and the various tissues and cells collected. BMD and body
weight measurements were performed before the first pI-pC injection and
before sacrifice, as previously described (O’Brien et al., 2005). Mice were
injected with tetracycline 6 and 2 days before harvesting. Protocols involving
genetically modified mice and their wild-type littermates were approved by
the Institutional Animal Care andUseCommittees of theUniversity of Arkansas
for Medical Sciences and the Central Arkansas Veterans Healthcare System.
Bone Analysis
Femur and vertebra micro-CT scans were performed on isolated bones with
a mCT40 scanning system (Scanco). Histology was performed in undecalcified
vertebral bone sections as previously described (Weinstein et al., 1998, 2002).etabolism 11, 136–146, February 3, 2010 ª2010 Elsevier Inc. 143
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Procedures.
Cell Culture
Osteoblastic cells derived from mouse calvaria were obtained and cultured
as described previously (Jilka et al., 1998) for 8 days. Adherent bone marrow
cells were obtained from long bones as described previously (DiGregorio
et al., 2001) and cultured in a-MEM supplemented with 10% FBS and 1%
PSG. Bone marrow-derived cells cultured in the absence of ascorbic acid
are designated stromal cells (Figures 3D and 3E). Cells cultured in the pres-
ence of 1% ascorbic acid to promote osteoblast differentiation are desig-
nated bone marrow osteoblastic cells (Figures 7D and 7E, Figures S1D and
S4). To quantify adipogenesis, bone marrow-derived stromal cells were
cultured to 70% confluence and the media supplemented with RGL (5 nM/ml)
or with 3.3% BSA in PBS as vehicle control. Medium was changed every
2 days for 11 days. Oil red O staining and quantification were performed as
described previously (Almeida et al., 2009a). Osteoclast progenitors were
derived from bone marrow cells cultured in a-MEM supplemented with
10% FBS, 1% PSG, 30 ng/ml M-CSF, and 30 ng/ml soluble RANKL (R&D
Systems). Osteoclasts were enumerated after staining for TRAP; only multi-
nucleated cells (more than three nuclei) were counted. Mature osteoclasts
were derived from nonadherent bone marrow cells maintained for 5 days
in the same medium as for osteoclast progenitors. Apoptotic cells were
quantified by measuring caspase-3 activity as described previously (Plotkin
et al., 1999).
Western Blot and qRT-PCR Analysis
Phosphorylated p66shc was assayed by immunoblotting in fifth lumbar
vertebra or cultured cell lysates, as previously described (Kousteni et al.,
2003) using a mouse monoclonal antibody recognizing Ser36 phosphorylated
p66shc (Calbiochem). FoxO1, FoxO3, and FoxO4 levels in cultured cell lysates
were determined using a rabbit monoclonal antibody for Foxo1 (Cell
Signaling), a rabbit polyclonal antibody for FoxO3 (Santa Cruz Biotechnology;
GenWay Biotech, Inc), and a rabbit polyclonal antibody for Foxo4 (Cell
Signaling). Protein levels of HA-FoxO3 or b-actin were analyzed using mouse
monoclonal antibodies (Cell Signaling and Sigma, respectively). Quantification
of the intensity of the bands in the autoradiograms was performed using a Ver-
saDoc imaging system (Bio-Rad). Total RNA was extracted from tissues or
cultured cells and reverse transcribed as previously described (Almeida
et al., 2007a). Primers and probes for the different genes were manufactured
by the TaqMan Gene Expression Assays service (Applied Biosystems).
Primers and probe for HA-FoxO3 were manufactured by Assays-on-Demand
service (Applied Biosystems): forward primer sequence 50-CTCTGACT
GACCGCGTTACTC-30; reverse primer sequence 50-GCCAAAATGATGAGA
CAGCACAATA-30. The mRNA levels in Figures 4C, 5B, 5C, and 7D and
Figure S1 were calculated by normalizing to the housekeeping gene ribosomal
protein S2 using the DCt method (Livak and Schmittgen, 2001). The relative
mRNA levels in Figure 1A, as well as in Figures 3A, 3D, 4A, and 4C and
Figure S4A were calculated by the same method with the additional step of
assigning an arbitrary value of 100 to the control sample.
Adenovirus Infection and Luciferase Assay
Newborn calvaria cells from Foxo3C or wild-type mice were infected twice
(with 24 hr interval) with adenovirus encoding Cre recombinase (Ad-Cre)
(Vector Biolabs) at a titer of 100 multiplicity of infection. Twenty-four hours
after the last infection, cells were plated on a 48-well plate and 16 hr later
transfected with a reporter plasmid containing six copies of daf-16 family
protein binding element (FoxO-luc) provided by B. Burgering (University
Medical Center, Utrecht, Netherlands) using Lipofectamine Plus (Invitrogen).
Luciferase activity was determined as previously described (Kousteni et al.,
2003).
Statistical Analysis
All data are reported as the mean ± standard deviation. Group mean values
were compared, as appropriate, by Student’s two-tailed t test or one-way
ANOVA with Bonferroni’s multiple comparison test. A p value %0.05 was
considered significant.144 Cell Metabolism 11, 136–146, February 3, 2010 ª2010 Elsevier InSUPPLEMENTAL INFORMATION
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